Immune Thrombocytopenic Purpura Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Immune Thrombocytopenic Purpura Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Immune thrombocytopenic purpura (ITP), is also called as Idiopathic thrombocytopenic purpura is a disease which leads to excessive bleeding and also results in the development of easy bruises. This condition takes place due to the excessive low platelet counts. Platelets help the blood to clot. The ITP affects both children and adults, the children may recover without treatment but for adults, it takes longer to recover. Other symptoms include bleeding from nose and gums, blood in urine and stools and an abnormally heavy menstrual flow.
The report provides Immune Thrombocytopenic Purpura treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Principia Biopharma, CSL, Syntimmune, Novartis AG and Sanofi among others.
Scope:
Immune Thrombocytopenic Purpura Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Immune thrombocytopenic purpura (ITP), is also called as Idiopathic thrombocytopenic purpura is a disease which leads to excessive bleeding and also results in the development of easy bruises. This condition takes place due to the excessive low platelet counts. Platelets help the blood to clot. The ITP affects both children and adults, the children may recover without treatment but for adults, it takes longer to recover. Other symptoms include bleeding from nose and gums, blood in urine and stools and an abnormally heavy menstrual flow.
The report provides Immune Thrombocytopenic Purpura treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Principia Biopharma, CSL, Syntimmune, Novartis AG and Sanofi among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
- Drug Name
- Generic Name
- Synonyms
- Company
- Collaborator
- Route of administration
- Target
- Mechanism of Action
- Technology
- Molecule type
- CAS Number
- Weight
- Chemical Formula
- IUPAC name
- ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Principia Biopharma
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. GlaxoSmithKline plc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Bristol-Myers Squibb Company
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Novartis AG
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Amgen Limited & Amgen Ireland Limited
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. PROTALEX, INC.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Argenx
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Immunomedics, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Sanofi
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. UCB S.A., Belgium
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. ILTOO Pharma
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Kyowa Hakko Kirin Co., Ltd
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Dova Pharmaceuticals
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Syntimmune
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Momenta Pharmaceuticals
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. CSL
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. GENOSCO INC.
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Hansa Medical AB
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
List of Tables
List of Figures
Companies Mentioned
- Principia Biopharma
- GlaxoSmithKline plc.
- Bristol-Myers Squibb Company
- Novartis AG
- Amgen Limited & Amgen Ireland Limited
- PROTALEX, INC.
- Argenx
- Immunomedics, Inc.
- Sanofi
- UCB S.A., Belgium
- ILTOO Pharma
- Kyowa Hakko Kirin Co., Ltd
- Dova Pharmaceuticals
- Syntimmune
- Momenta Pharmaceuticals
- CSL
- GENOSCO INC.
- Hansa Medical AB
Methodology
LOADING...
